Susquehanna International Group
NTLA icon

Susquehanna International Group’s Intellia Therapeutics NTLA Stock Holding History

Susquehanna International Group’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.58M Sell
513,400
-66,500
-11% -$847K ﹤0.01% 3776
2025
Q4 		$5.21M Buy
579,900
+133,200
+30% +$1.83M ﹤0.01% 3948
2025
Q3 		$7.71M Buy
446,700
+289,000
+183% +$3.56M ﹤0.01% 3392
2025
Q2 		$1.48M Sell
157,700
-1,200
-0.8% -$9.85K ﹤0.01% 6483
2025
Q1 		$1.13M Sell
158,900
-178,700
-53% -$1.8M ﹤0.01% 6935
2024
Q4 		$3.94M Sell
337,600
-55,500
-14% -$866K ﹤0.01% 3982
2024
Q3 		$8.08M Sell
393,100
-900
-0.2% -$20.8K ﹤0.01% 2912
2024
Q2 		$8.82M Buy
394,000
+142,000
+56% +$3.38M ﹤0.01% 2649
2024
Q1 		$6.93M Sell
252,000
-80,900
-24% -$2.25M ﹤0.01% 3138
2023
Q4 		$10.2M Buy
332,900
+234,600
+239% +$6.74M ﹤0.01% 2628
2023
Q3 		$3.11M Sell
98,300
-181,600
-65% -$7.05M ﹤0.01% 4321
2023
Q2 		$11.4M Buy
279,900
+144,100
+106% +$5.84M ﹤0.01% 2348
2023
Q1 		$5.06M Sell
135,800
-300
-0.2% -$11.8K ﹤0.01% 3456
2022
Q4 		$4.75M Sell
136,100
-8,600
-6% -$409K ﹤0.01% 3319
2022
Q3 		$8.1M Buy
144,700
+15,100
+12% +$937K ﹤0.01% 2455
2022
Q2 		$6.71M Buy
129,600
+21,900
+20% +$1.11M ﹤0.01% 2745
2022
Q1 		$7.83M Buy
107,700
+24,500
+29% +$2.08M ﹤0.01% 2892
2021
Q4 		$9.84M Sell
83,200
-77,200
-48% -$9.67M ﹤0.01% 2738
2021
Q3 		$21.5M Sell
160,400
-304,500
-65% -$46.1M ﹤0.01% 1898
2021
Q2 		$75.3M Buy
464,900
+395,700
+572% +$30.8M 0.01% 926
2021
Q1 		$5.55M Sell
69,200
-39,000
-36% -$2.62M ﹤0.01% 3704
2020
Q4 		$5.89M Buy
108,200
+72,400
+202% +$2.63M ﹤0.01% 3179
2020
Q3 		$712K Sell
35,800
-10,100
-22% -$211K ﹤0.01% 6927
2020
Q2 		$965K Buy
45,900
+14,700
+47% +$250K ﹤0.01% 6015
2020
Q1 		$382K Sell
31,200
-3,300
-10% -$44.5K ﹤0.01% 7499
2019
Q4 		$506K Buy
34,500
+5,300
+18% +$73.7K ﹤0.01% 6961
2019
Q3 		$390K Buy
29,200
+11,500
+65% +$183K ﹤0.01% 7793
2019
Q2 		$290K Sell
17,700
-19,600
-53% -$308K ﹤0.01% 8386
2019
Q1 		$637K Sell
37,300
-700
-2% -$10.4K ﹤0.01% 5838
2018
Q4 		$519K Sell
38,000
-35,300
-48% -$656K ﹤0.01% 5974
2018
Q3 		$2.1M Sell
73,300
-11,400
-13% -$332K ﹤0.01% 3903
2018
Q2 		$2.32M Sell
84,700
-130,200
-61% -$3.15M ﹤0.01% 3766
2018
Q1 		$4.53M Buy
214,900
+139,500
+185% +$3.43M ﹤0.01% 2670
2017
Q4 		$1.45M Sell
75,400
-13,100
-15% -$302K ﹤0.01% 4525
2017
Q3 		$2.2M Buy
88,500
+56,600
+177% +$1.07M ﹤0.01% 3735
2017
Q2 		$510K Buy
31,900
+6,500
+26% +$90.8K ﹤0.01% 6605
2017
Q1 		$358K Buy
+25,400
New +$341K ﹤0.01% 7071

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Susquehanna International Group's NTLA Position: Q1 2026 in Review

Susquehanna International Group reduced its Intellia Therapeutics (NTLA) stake by 14% in Q1 2026, selling an estimated $1.11M and leaving 521,465 shares worth $6.69M. The position accounts for ﹤0.01% of the portfolio, ranked #3747.

Susquehanna International Group first reported a position in NTLA in Q4 2016 and has held it in 34 quarters since. The position peaked at $15.4M in Q3 2025. 303 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • Susquehanna International Group held 521,465 shares of Intellia Therapeutics worth $6.69M as of Q1 2026.
  • Susquehanna International Group sold 87,200 Intellia Therapeutics shares in Q1 2026, an estimated $1.11M.
  • Intellia Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #3747 holding.
  • Susquehanna International Group first reported a position in Intellia Therapeutics in Q4 2016 and has held it in 34 quarters since.
  • Susquehanna International Group's Intellia Therapeutics position peaked at $15.4M in Q3 2025.
  • 303 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.